• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

23.75 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,106
Open 23.75
Bid (Size) 23.60 (1,000)
Ask (Size) 24.75 (100)
Prev. Close 23.75
Today's Range 23.75 - 23.75
52wk Range 16.35 - 31.73
Shares Outstanding 125,300,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day ↗
Today 5:02 EDT
Arcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and... 
Via MarketBeat
News headline image
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
October 20, 2026
From Arcus Biosciences
Via Business Wire

Performance

52-Week Range 25.2% below 52-week high
23.75
16.3552W Low 31.7352W High
1 Week 3.8% below 1-week high
20.811W Low 24.701W High

Arcus Biosciences, Inc. Common Stock (RCUS) traded between $16.35 and $31.73 over the past 52 weeks and last traded at $23.75, 25.2% below its 52-week high. Over the past week it ranged between $20.81 and $24.70.

Past 12 Months
+5.4%
-8.5%
-19.4%
-3.1%
+2.0%
+35.9%
1W +$1.22
1M -$2.20
3M -$5.73
6M -$0.77
YTD +$0.46
1Y +$6.28

RCUS was +35.9% over the past year, -3.1% over six months, +2.0% year to date, +5.4% in the last week.

12 Months vs Market
RCUS
+35.9%
DIA
+12.3%
SPY
+14.6%
QQQ
+17.3%
IWM
+11.1%

Over the past 12 months RCUS returned +35.9% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.01× 3-mo avg
Today 20,106 3-mo avg 1.5M
1W
2.7M
1M
1.7M
3M
1.5M
6M
1.4M
YTD
1.3M
1Y
1.5M

RCUS most recently traded 20,106 shares against a 3-month average daily volume of 1.5M.

More News

Read More
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
October 09, 2026
From Arcus Biosciences
Via Business Wire
Arcus Biosciences (NYSE:RCUS) Flashes a High-Quality Technical Breakout Setup ↗
August 27, 2026
Via Chartmill
Arcus Biosciences (NYSE:RCUS) Beats Q2 Estimates and Advances Casdatifan Pipeline ↗
August 05, 2026
Via Chartmill
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
September 24, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
September 22, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
September 09, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
August 26, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
August 11, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Q2 Earnings Call Highlights ↗
August 08, 2026
Via MarketBeat
Topics Earnings
News headline image
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
August 05, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
July 27, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
July 22, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
July 21, 2026
From Arcus Biosciences
Via Business Wire
News headline image
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run ↗
July 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
July 09, 2026
From Arcus Biosciences
Via Business Wire
News headline image
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
July 01, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
June 24, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
June 09, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
June 03, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
From Arcus Biosciences
Via Business Wire
News headline image
Arcus (RCUS) Q1 2026 Earnings Call Transcript ↗
May 05, 2026
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Arcus Biosciences, Inc. Common Stock publicly traded?
Yes, Arcus Biosciences, Inc. Common Stock is publicly traded.
What exchange does Arcus Biosciences, Inc. Common Stock trade on?
Arcus Biosciences, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Arcus Biosciences, Inc. Common Stock?
The ticker symbol for Arcus Biosciences, Inc. Common Stock is RCUS on the New York Stock Exchange
What is the current price of Arcus Biosciences, Inc. Common Stock?
The current price of Arcus Biosciences, Inc. Common Stock is 23.75
When was Arcus Biosciences, Inc. Common Stock last traded?
The last trade of Arcus Biosciences, Inc. Common Stock was at 10/20/26 07:00 PM ET
What is the market capitalization of Arcus Biosciences, Inc. Common Stock?
The market capitalization of Arcus Biosciences, Inc. Common Stock is 2.98B
How many shares of Arcus Biosciences, Inc. Common Stock are outstanding?
Arcus Biosciences, Inc. Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap